Anemia, tumor hypoxemia, and the cancer patient

International Journal of Radiation Oncology Biology Physics

Volumn 63, Issue 1, 2005, Pages 25-36

  Varlotto, John ^a,b   Stevenson, Mary Ann ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anemia; Anemia correction; Cancer patients; Erythropoietin; Hypoxemia; Transfusion

Indexed keywords

CELLS; GROWTH KINETICS; HORMONES; IMMUNOLOGY; PATIENT MONITORING; PATIENT TREATMENT; RADIOTHERAPY; TUMORS;

ANEMIA CORRECTION; CANCER PATIENTS; HYPOXEMIA; TRANSFUSION;

EPIDEMIOLOGY;

ANTINEOPLASTIC AGENT; CARBOGEN; CARBOPLATIN; CISPLATIN; EFAPROXIRAL; ETANIDAZOLE; FLUOROURACIL; HEMOGLOBIN; IFOSFAMIDE; JANUS KINASE 2; MISONIDAZOLE; MITOMYCIN; NICOTINAMIDE; NIMORAZOLE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PROTEIN BCL X; RADIOSENSITIZING AGENT; RECOMBINANT ERYTHROPOIETIN; STAT5 PROTEIN; TIRAPAZAMINE; ERYTHROPOIETIN;

ANEMIA; APOPTOSIS; BLOOD TRANSFUSION; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE ASSOCIATION; GENE MUTATION; HEAD AND NECK CANCER; HEMOGLOBIN DETERMINATION; HUMAN; HYPERBARIC OXYGEN; HYPOXEMIA; IMMUNE DEFICIENCY; LUNG NON SMALL CELL CANCER; MEDLINE; META ANALYSIS; MULTICENTER STUDY; OXYGENATION; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; RADIOSENSITIZATION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER; NEOPLASM; RADIATION DOSE;

ANEMIA; ANOXEMIA; BLOOD TRANSFUSION; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; HYPERBARIC OXYGENATION; NEOPLASMS; PRACTICE GUIDELINES; QUALITY OF LIFE; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 26944497269     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.04.049     Document Type: Article

References (100)

1. Means RT, Krantz S. Progress in understanding the pathogenesis of anemia of chronic disease. Blood 1992;80:1639-1647.
2. Harrison LB, Chadha M, Hill RJ, et al. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002;7:492-508.
3. Lee WR, Berkey B, Marcial V, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998;42:1069-1075.
4. Harrison LB, Shasha D, White C, Ramdeen B. Radiotherapy-associated anemia: The scope of the problem. Oncologist 2000;5:1-7.
5. Demetri GD. Anemia and its functional consequences in cancer patients: Current challenges in management and prospects for improving therapy. Br J Cancer 2001;84(Suppl. 1): 31-37.
6. Asbell SO, Leon SA, Tester WJ, et al. Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate 1996;29:243-248.
7. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34:13-19.
8. Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer. Cancer 2001;91:2214-2221.
9. Ania BJ, Sumam VJ, Fairbucks VF, et al. Incidence of anemia in older people: An epidemiologic study in a well-defined population. J Am Geriatr Soc 1997;45:825-831.
10. Xiu H, Ebben J, Mu J, et al. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephr 1999; 10:1309-1316.
11. Glaspy JA. The potential for anemia treatment to improve survival in cancer patients. Oncology 2002;16:35-40.
12. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-4515.
13. Lutterbach J, Guttenberger R. Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic larynx. Int J Radiat Oncol Biol Phys 2000;48:1345-1350.
14. Teicher BA, Holden SA, al-Achi A, et al. Classification of anti-neoplastic treatments by the differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in FSaHC murine fibrosarcoma. Cancer Res 1990;50:3339-3344.
15. Green SL, Giaccia AJ. Tumor hypoxia and the cell cycle: Implications for malignant progression and response to therapy. Cancer J Sci Am 1998;4:218-223.
16. Palcic B, Skarsgard LD. Reduced oxygen enhancement ratio at low doses of ionizing radiation. Radiat Res 1984;100:328-339.
17. Hall EJ. Oxygen effect and reoxygenation. in radiobiology for the radiologist. Philadelpia: Lippincott, Williams, and Wilkins; 2000. p. 94-95.
18. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group Randomized Trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76.
19. Semenza GL. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002;64:993-998.
20. Jelkmann W, Hellwig-Burgel T. Biology of erythropoietin. In: Roach RC, editor. Hypoxia: from genes to the bedside. London:Kluwer Academic/Plenum Publishers; 2001.
21. Richard DE, Berra E, Pouyssegur J. Angiogenesis: How a tumor adapts to hypoxia. Biochem Biophys Res Commun 1999;266:718-722.
22. Lund EL, Hog A, Olsen MW, et al. Differential regulation of VEGF, HIF-1 alpha and angiopoietin-1, 2, and 4 by hypoxia and ionizing radiation in human glioblastoma. Int J Cancer 2004;108:833-838.
23. Dai S, Huang M, Hsu C, et al. Inhibition of hypoxia inducible factor 1 alpha causes oxygen-independent cytotoxicity and induces p53 independent apoptosis in glioblastoma cells. Int J Radiat Oncol Biol Phys 2003;55:1027-1036.
24. Reynolds TY, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res 1996;56:5754-5757.
25. Yuan J, Glazer PM. Mutagenesis induced by the tumor microenvironment. Mutat Res 1998;400:439-446.
26. Brizel DM, Dodge RK, Clough RW, et al. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53: 113-117.
27. Hockel M, Knoop C, Schlenger K, et al. Intratumoral pO2 predicts survival in advance cancer of the uterine cervix. Radiother Oncol 1993;26:45-50.
28. Stadler P, Becker A, Feldmann HJ, et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999;44:749-754.
29. Dunst J, Stadler P, Becker A, et al. Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onkol 2003; 179:521-526.
30. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41:31-39.
31. Dietz A, Rudat V, Conradt C, et al. Prognostic value of hemoglobin level for primary radiochemotherapy of head and neck carcinomas. HNO 2000;48:655-664.
32. Rudat V, Vanselow B, Wollensack P, et al. Repeatability and prognostic impact of the pretreatment pO2 histography in patients with advanced head and neck cancer. Radiother Oncol 2000;57:31-37.
33. Rofstad EK, Sundfor K, Lyng H, et al. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 2000;83:354-359.
34. Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. 1999;86:1528-1536.
35. Kapp KS, Poschauko J, Geyer E, et al. Evaluation of the effect of routine packed red blood cell transfusion in anemic cervix cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2002;54:58-66.
36. Daly T, Poulsen MG, Denham JW, et al. The effect of anemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Radiother Oncol 2003;68: 113-122.
37. Hong JH, Tsai CS, Chang JT, et al. The prognostic significance of pre- and posttreatment SCC level in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:823-830.
38. Kagei K, Shirato H, Nishioka T, et al. High-dose-rate intracavitary irradiation using linear source arrangement for stage II and III squamous cell carcinoma of the cervix. Radiother Oncol 1998;47:207-213.
39. Fein DA, Lee WR, Hanlon AL, et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995;13:2077-2083.
40. Dubray B, Mosseri V, Brunin F, et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: A prospective study. Radiology 1996;201:553-558.
41. Warde P, O'Sullivan B, Bristow RG, et al. T1/T2 glottic cancer managed by external beam radiotherapy: The influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 1998;41:347-353.
42. Takeshi K, Katsuyuki K, Yoshiaki T, et al. Definitive radiotherapy combined with high-dose-rate brachytherapy for stage III carcinoma of the uterine cervix: Retrospective analysis of prognostic factors concerning patient characteristics and treatment parameters. Int J Radiat Biol Phys 1998;41: 319-327.
43. MacRae R, Shyr Y, Johnson D, et al. Declining hemoglobin during chemoradiotherapy for locally advance non-small cell lung cancer is significant. Radiother Oncol 2002;64:37-40.
44. Langendijk H, de Jong J, Wanders R, et al. The Importance of pre-treatment haemoglobin level in inoperable non-small cell lung carcinoma treated with radical radiotherapy. Radiother Oncol 2003;67:321-325.
45. Altun M, Demiral AN, Meral R, et al. Prognostic significance of hemoglobin concentration in nasopharyngeal carcinoma: Does treatment-induced anemia have negative effect? In Vivo 2003;17:483-487.
46. Schafer U, Micke O, Muller SB, et al. Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors. Strahlenther Onkol 2003;179:527-534.
47. Macdonald G, Hurman DC. Influence of anemia in patients with head and neck cancer receiving adjuvant postoperative radiotherapy in the Grampian. Clin Oncol 2004;16:63-70.
48. Dunst J, Kuhnt T, Strauss HG, et al. Anemia in cervical cancers: Impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 2003;56:778-787.
49. Obermair A, Cheuk R, Horwood K, et al. Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma: preliminary results. Cancer 2001;92:903-908.
50. Thomas G. The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. Semin Oncol 2001; 28(Suppl. 8):60-65.
51. Clavo B, Perez JL, Lopez L, et al. Influence of haemeglobin concentration and peripheral muscle pO2 on tumor oxygenation in advanced head and neck tumors. Radiother Oncol 2003;66:71-74.
52. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;59:67-71.
53. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996;6:10-21.
54. Kaanders JH, Bussink J, van der Kogel AJ. ARCON: A novel biology-based approach in radiotherapy. Lancet Oncol 2002;3:728-37.
55. Shaw E, Scott C, Suh J, et al. RSR13 plus cranial radiation therapy in patients with brain metastases: Comparison with the radiation therapy oncology group recursive partitioning analysis brain metastases database. J Clin Oncol 2003;21: 2364-2371.
56. Kleinberg L, Grossman SA, Carson K, et al. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: Results of a phase II new approaches to brain tumor therapy. CNS Consortium Safety and Efficacy Study. J Clin Oncol 2002;20:3149-3155.
57. Kavanagh BD, Khandelwal SR, Schmidt-Ullrich RK, et al. A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics. Int J Radiat Oncol Biol Phys 2001;49:1133-1139.
58. Hall EJ. Radiosensitizers and bioreductive drugs. In: Hall EC, editor; Radiobiology for the radiologist. Philadelphia: Lippincott, Williams, and Wilkins, 2000; p. 94-95.
59. Lee DJ, Cosmatos D, Marcial VA, et al. Results of an RTOG Phase III Trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 1995;32:567-576.
60. Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46:135-146.
61. Plumb JA, Workman P. Unusually marked hypoxic sensitization to indoloquinoneEO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer 1994;56:134-139.
62. Haffty BG, Son YH, Papac R, et al. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale Mitomycin Randomized Trials. J Clin Oncol 1997;15:268-276.
63. Roberts KB, Urdaneta N, Vera R, et al. Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix. Int J Cancer 2003;90:206-223.
64. Brown JM, Wang LH. Tirapazamine: Laboratory date relevant to clinical activity. Anticancer Drug Des 1998;13:529-539.
65. von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the International CATAPULT I Study Group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 2000;18:1351-1359.
66. Risshin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:535-542.
67. Craighead PS, Pearcey R, Stuart G. A PhaseI-II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2000;48:791-795.
68. Mock V, Atkinson A, Barsevick A, et al. Cancer-related fatigue. J Natl Comprehensive Cancer Network 2003;1:308-331.
69. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
70. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: A systemic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001;93:1204-1214.
71. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
72. Abels RI. Recombinant human erythropoietin in the treatment of the anemia of cancer. Acta Haematol 1992;87(Suppl. 1):4-11.
73. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403.
74. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: Randomized, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
75. Koury MJ, Bondurant MC. The molecular mechanism of erythropoietin action. Eur J Biochem 1992;210:649-663.
76. Yasuda Y, Furita Y, Matsuo T, et al. Erythropoietin regulates tumor growth of human malignancies. Carcinogenesis 2003; 24:1021-1029.
77. Henke M, Bechtold C, Momm F, et al. Blood hemoglobin level may affect radiosensitivity-preliminary results on acutely reacting normal tissues. Int J Radiat Biol Phys 2000; 48:339-345.
78. Marinaccio M, Mele E, Giotta F. Pretreatment normalization of mild anemia with epoetin alfa: impact on the outcome in epithelial ovarian cancer patients [Abstract]. Proc Am Soc Clin Oncol 2003;22:486.
79. Blohmer JU, Wurschmidt U, Petry G. 6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study: Sequential adjuvant chemo-radiotherapy with vs. without epoetin alfa for patients with high risk cervical cancer [Abstract]. Proc Am Soc Clin Oncol 2003;22:447.
80. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
81. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993;90:4304-4308.
82. Parganas E, Wang D, Stravopodis, et al. Jak2 is essential for signaling though a variety of cytokine receptors. Cell 1998; 93:385-395.
83. Weiss MJ. New Insights into erythropoietin and epoetin alfa: Mechanisms of action, target, tissues, and clinical applications. Oncologist 2003;8(Suppl. 3):18-29.
84. Jaquet K, Krause K, Tawakol-Khodai M, et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002;64:326-333.
85. Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999; 93:2627-2636.
86. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999;55:808-820.
87. Feldman L, Wang Y, Rhim JS, et al. Human prostate epithelial and prostate cancer cells express both erythropoietin and functional erythropoietin receptors. Proc Am Soc Hematol 2002; 100:171b.
88. Buemi M, Cavallaro E, Floccari F, et al. The pleiotropic effects of erythropoietin in the central nervous system. J Neuropathol Exp Neurol 2003;62:228-236.
89. Senzer N. Rationale for a phase III study of erythropoietin as a neurocognitive protectant in patients with lung cancer receiving prophylactic cranial irradiation. Semin Oncol 2002; 29(Suppl. 6):47-52.
90. Verhelst D, Rossert J, Casadevall N, et al. Treatment of erythropoietin-induced pure red cell aplasia: A retrospective study. Lancet 2004;363:1768-1771.
91. Gemignani M, Zakashansky K, Venkatraman D. Blood transfusion in radical hysterectomy and pelvic lymphadenectomy for invasive cervical cancer: Impact on recurrence and overall survival [Abstract]. Proc Am Soc Clin Oncol 2003;22:454.
92. Santin AD, Bellone S, Parrish RS, et al. Influence of allogeneic blood transfusion on clinical outcome during radiotherapy for cancer of the uterine cervix. Gynecol Obstet Invest 2003;56:28-34.
93. Santin A, Belone S, Palmieri M, et al. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: Role of interleukin-10. Int J Radiat Oncol Biol Phys 2002;54:1345-1355.
94. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001; 85:473-483.
95. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545.
96. Weitz J, D'Angelica M, Gonen M, et al. Interaction of splenectomy and peri-operative blood transfusions on prognosis of patients with proximal gastric and gastroesophageal junction cancer. J Clin Oncol 2003;21:4597-4603.
97. Sy MS, Miller SD, Kowach WB, et al. A splenic requirement for the generation of suppressor T cells. J Immunol 1977; 119:2095-2099.
98. Dzik WH. Apoptosis, TGFBeta, and transfusion-related immunosuppression: Biologic versus clinical effects, transfusion and apheresis. Science 2003;29:127-129.
99. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342:1350-1358.
100. Gharehbaghian A, Haque K, Truman C, et al. Effect of autologous salvaged blood on the postoperative natural killer cell precursor frequency. Lancet 2004;363:1025-1030.